ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that...
Month: January 2025
The Ensign Group Closes on Expansion in Tennessee, Adds Its First Operation in Alabama
SAN JUAN CAPISTRANO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the EnsignTM group...
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO...
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentationMarlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp....
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Topline data from the chronic cohort is expected in Q2 2025Institutional Review Board (IRB) protocol amendment changes approved, and screening...
Delota Reports Third Quarter Revenue of $10.3 Million; $29.9 Million for the Nine Months Ended 2025 and Third Consecutive Quarter of Positive Adjusted EBITDA
Highlights:Total revenue of $10.3 million for Q3 2025, reflecting YoY growth of 27% from the comparative quarter37% gross profit margin...
Hisense Ranked No.1 in MEA for Large-Screen and MiniLED TV Shipments
DUBAI, UAE, Jan. 2, 2025 /PRNewswire/ -- Hisense, a global leader in consumer electronics and home appliances, has achieved a...
SMART 2025: Shaping the Future of Wellness During CES Week
LAS VEGAS, Jan. 1, 2025 /PRNewswire/ -- AI Wellness proudly launches the SMART 2025 Initiative during CES Week, setting the stage for...
Introducing the CodyMD Crypto Plan
(Now your health can be as cutting-edge as your wallet in 2025.) PORTLAND, Ore., Jan. 1, 2025 /PRNewswire/ -- CodyMD https://cody.md is...
re:3D announces OrthoAdditive Africa as the recipient of the 2024 Gigaprize competition; the organization will receive an industrial 3D printer to help pursue their mission in South Africa
AUSTIN, Texas, Jan. 1, 2025 /PRNewswire/ -- re:3D, Inc. is pleased to announce the winner of the 2024 Gigaprize competition....
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative...
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
Provides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term cash needsSAN DIEGO, Dec. 31,...
Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology
Innovative Solutions Transform Treatment for Burn Victims, Chronic Wounds, and Scar ReductionCHICAGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Stem Health...
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...
Hamershlag Private Capital Management Limited Makes $150 Million Venture Structured Investment in Patho Care, LLC via PathoCare Holdings, Inc.
HOUSTON--(BUSINESS WIRE)--Hamershlag Private Capital Management Limited (HPCM), a leading health technology investment firm, has announced a significant venture investment in...